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Background: Limbal stem cell (LSC) deficiency leads to corneal opacity due to a conjunc-
tivalization of the corneal surface. LSC transplantation, which can be followed by corneal 
keratoplasty, is an effective procedure to restore corneal transparency; however, a common 
cause of failure of this procedure is neovascularization (NV).
Methods: A 59-year-old man with a 21-year history of a corneal chemical burn caused by 
phosphoric acid in his left eye was examined. He presented with unilateral total LSC deficiency 
with severe conjunctivalization and a corrected distance visual acuity that was limited to hand 
motion.
Results: We reported the short-term in vivo efficacy of subconjunctival bevacizumab for 
progressive corneal NV in a patient with LSC deficiency that underwent LSC transplantation. 
Four months after autologous LSC transplantation and 1 month after the second subconjunctival 
bevacizumab injection, the patient’s corrected distance visual acuity was 1/10.
Conclusion: Subconjunctival injection of bevacizumab can reduce the corneal NV, reducing 
conjunctival inflammation and supporting restoration of a stable ocular surface that is able to 
counteract graft failure, with no toxicity for the transplanted LSC.
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Introduction
The human cornea is known to be an avascular and transparent tissue. Its avascularity 
is maintained by both an appropriate balance between antiangiogenic and antilymph-
angiogenic factors, as well as by the integrity of limbal stem cell (LSC) barriers.1,2 
A wide variety of insults, such as infections, inflammation, ischemia, degeneration, 
and trauma, can disrupt this balance, leading to corneal neovascularization (NV).1 
Corneal NV results in a loss of transparency and the consequent loss of visual 
acuity, lipid deposition, tissue scarring, edema, and a loss of immune privilege, with 
the progressive worsening of a patient’s prognosis.3 Several studies have shown that a 
key role in NV is played by the vascular endothelial growth factor (VEGF) family. In 
fact, increased levels of corneal VEGF and VEGF receptors have been demonstrated 
in vascularized cornea.4
Bevacizumab is a humanized monoclonal antibody targeting the VEGF, and which 
has been approved as a first-line therapy for widespread metastatic colorectal cancer. 
Numerous trials have been published on the off-label intravitreal injection of beva-
cizumab in ophthalmology, especially for the treatment of neovascular age-related 
macular degeneration, proliferative diabetic retinopathy, macular edema from central 
retinal vein occlusion, and refractory pseudophakic cystoid macular edema.5
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Recently, bevacizumab has been used for the treatment of 
anterior segment NV with promising results in the regression 
of iris NV, neovascular glaucoma, and corneal NV. More-
over, subconjunctival injections and topical applications of 
this molecule have shown no toxicity for corneal tissue.6
In the event of corneal opacity, allogenic corneal transplan-
tation (keratoplasty) can be performed in order to restore corneal 
transparency. However, in the event of LSC deficiency, ker-
atoplasty is only temporarily effective; a common occurrence 
with the procedure is corneal conjunctivalization, which means 
that there is an invasion of the corneal surface by conjunctival 
cells with the formation of a conjunctival pannus.7 As is known, 
corneal epithelial renewal is accomplished by the proliferative 
activity of stem cells located in the limbus, which is a narrow 
zone that lies between the cornea and the bulbar conjunctiva.8 
LSC transplantation can restore corneal regenerative function, 
preparing the corneal surface for keratoplasty. However, despite 
an immediately satisfying result, corneal NV can occur. 
To our knowledge, no studies have been published regard-
ing the possible use of bevacizumab in the event of corneal 
NV secondary to LSC transplantation. We report the short-
term in vivo efficacy of subconjunctival bevacizumab for 
the treatment of recurring corneal NV in a patient with LSC 
deficiency (LSCD) who underwent LSC transplantation.
Methods
A 59-year-old man with a 21-year history of chemical burn of 
the cornea caused by phosphoric acid in his left eye presented 
to our hospital with unilateral total LSCD, severe corneal 
conjunctivalization, cataract, and a corrected distance visual 
acuity (CDVA) limited to hand motion in the affected eye.
The patient underwent a 2×2 mm biopsy of the limbus 
from the fellow eye; the biopsy material was cultivated on 
fibrin, a natural substrate that preserves holoclone-forming 
cells (Centre for Regenerative Medicine, Department of 
Biomedical Science, University of Modena and Reggio 
Emilia, Rome, Italy). Cultured autologous LSC transplanta-
tion was performed.
The fibrin-cultured epithelial sheet has been grafted 
over the corneal and limbal region of the injured eye, where 
the receiving bed had been previously surgically prepared. 
A 360° peritomy was performed and the fibrovascular pannus 
was carefully removed.9,10 The fibrin-cultured epithelial 
sheet was placed on the prepared corneal wound bed, span-
ning the limbus about 2–3 mm to reduce competition with 
conjunctival in-growth. The conjunctiva was then sutured 
over the peripheral fibrin sheet with an 8.0 vicryl suture in 
order to protect the border of the sheet and to help it adhere 
on the corneal surface (Figure 1).7
Results
The preoperative CDVA was limited to hand motion. Three 
days before the autologous LSC transplantation, the patient’s 
CDVA was 1/100. The corneal surface was regular and trans-
parent; there was peripheral edema in the nasal sector, and a 
stromal opacity was evident in the superonasal sector.
Renewal of the corneal epithelium appeared within the 
first week after transplantation. Two weeks after surgery, the 
patient’s best corrected visual acuity was 2/50. After 30 days 
from transplantation, we observed almost complete corneal 
epithelium renewal, a regression of peripheral edema, and 
progressive corneal NV from the conjunctival tissue at the 
12 o’clock and 6 o’clock positions. To reduce the incoming 
limbal NV, two subconjunctival bevacizumab injections were 
performed 2 months and 3 months after transplantation. 
Commercially available bevacizumab (Avastin®; 
Hoffman-La Roche Ltd., Basel, Switzerland) was injected at 
a dose of 2.5 mg (0.1 mL). The injections were administered 
in the subconjunctival space close to the corneal limbus and 
adjacent to the area containing the pathological vessels.6 
Four months after the autologous LSC transplantation 
and 1 month after the second subconjunctival bevacizumab 
Figure 1 surgical procedure.
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Chemical injury treated with epithelial stem cells
injection was performed, the patient’s CDVA was 1/10. 
Subconjunctival bevacizumab successfully decreased corneal 
NV and at 1 month after the second injection, the corneal 
surface appeared to be regular, transparent, and with no 
evidence of limbal NV (Figure 2). 
Discussion
Autologous LSC transplantation is an effective technique 
for the treatment of corneal chemical burns resulting in a 
LSCD.7 In this case report, we used a technique described in 
literature guidelines.7–9 The aim of this study was to report the 
(off-label) subconjunctival injection of bevacizumab to avoid 
corneal NV, which can cause autologous LSC transplantation 
to fail. Our patient underwent two injections of subconjuncti-
val bevacizumab that were administered 1 month apart from 
each other, resulting in progressive corneal NV slowdown 
(Figure 2), and a decrease in conjunctival inflammation.
Limbal epithelial stem cell transplantations can be suc-
cessful in patients with LSCD for the reconstruction of the 
ocular surface, and they can restore the patient’s clinical 
condition so it can allow for a corneal graft with reduced 
risk of rejection. Subconjunctival injection of bevacizumab is 
an easy procedure that successfully reduces corneal NV and 
conjunctival inflammation, restoring a stable ocular surface 
that is able to counteract graft failure with no toxicity for the 
transplanted LSCs.
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Figure 2 Corneal neovascularization.
Notes: (A) One day after autologous limbal stem cell transplantation; (B) limbal neovascularization 30 days after transplantation; and (C) corneal surface and regression of 
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